mardi 26 juin 2018

Onco Actu du 26 juin 2018

1. Biologie

Researchers discover new type of lung cancer [Cold Spring Harbor Lab]

2.6 Etiologie - Environnement

Flight attendants may have higher cancer rates [Reuters]

3. Prévention

3Q: Nancy Hopkins on the impact and potential of cancer prevention [MIT News]

3.2 Prévention - Obésité

Cancer Research UK responds to the Governments new Childhood Obesity Plan [Cancer Research UK]

4.12 Biopsies liquides

Bio-Techne to Acquire Liquid Biopsy Firm Exosome Diagnostics for $250M [Xconomy]

4.5 Dép., diag. & prono. - Colorectal

Celebrity colonoscopy parties – great fun ‘every other year’? [HealthNewsReview]

5. Traitements

Is chemo obsolete? Not by a long shot, cancer experts say [NBC News]

5.10 Traitements - Essais

In rare slip, Pfizer steamroller Ibrance fails to show it helps patients live longer [FiercePharma]

Oops. Pfizer’s CDK 4/6 blockbuster Ibrance flunks the OS mark for breast cancer [EndPoints]

Pfizer's breast cancer drug combo falls short of survival goal [Reuters]

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer [Business Wire]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

AbbVie and Calibr announce collaboration for next generation T-cell therapies [The Scripps Research Institute]

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr [EndPoints]

5.12.3 Immunothérapies-combinaisons

Lethal Prostate Cancer Treatment May Benefit from Combination Immunotherapy [Johns Hopkins]

5.12.4 Immunothérapies - Essais

With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche? [FiercePharma]

IMpower133 Study Met Co-primary Endpoints at First Interim Analysis [ESMO]

With Roche Data, Cancer Combos Post First Win Vs. Small Cell Lung Cancer [Xconomy]

5.12.5 Immunothérapies - Pharma

FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma [Merck]

5.2 Pharma

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer [AbbVie]

Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer [Merrimack]

Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat [EndPoints]

Sudden death forces Sophiris to halt followup therapy in prostate cancer study [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

FDA to release list of surrogate endpoints in oncology [EndPoints]

6.1 Observation

NHS among worst in Western world at preventing avoidable deaths, study finds [The Telegraph]

Some adult survivors of childhood cancer unconcerned about health [Reuters]

NHS 'worse than average in treating eight common causes of death' [The Guardian]

6.10.1 Politiques (USA)

FDA should be split up—and stop covering food, says White House [FierceBiotech]

6.11 Patients

Cancer patients face 'absurd' travel insurance costs [BBC News]

6.5 Médecines alternatives

Clínica 0-19: False hope in Monterrey for brain cancer patients [Science-Based Medicine]